Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433782 | 0.95 | SLC6A4 (0.51) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL2200912 | 0.92 | SLC6A4 (0.43) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL31567064 | 0.84 | SLC6A4 (0.38) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL17157386 | 0.84 | WDR5 (0.41) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL18742666 | 0.84 | WDR5 (0.41) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL625872 | 0.84 | SLC6A4 (0.38) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL31567211 | 0.83 | OPRM1 (0.39) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL2290702 | 0.83 | PDE4A (0.48) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL625339 | 0.82 | KCNN4 (0.39) | SLC6A4SLC6A3NPC1ALDH1A1RAB9A | |
| SCHEMBL624379 | 0.82 | KIF11 (0.43) | NPC1ALDH1A1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| EP-3362445-B1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-01-25 | — | — | EP | disclosed |
| US-20180273495-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-27 | — | — | US | disclosed |
| EP-3362445-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017065473-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017065473-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-20 | — | — | WO | disclosed |
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1532122-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK SHARP & DOHME LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003104208-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104207-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | HSD11B1, HSD17B1, HSD11B2 | SLC6A4 1029/4885SLC6A3 1188/4885NPC1 177/4885 |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | SLC6A4 828/4885SLC6A3 797/4885NPC1 235/4885 |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | SLC6A4 511/4885SLC6A3 717/4885NPC1 1833/4885 |
| US-20180273495-A1 | OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | SLC6A4 3090/4885SLC6A3 3342/4885NPC1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.